Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Japanese encephalitis vaccine (Vero cell), inactivated is a viral vaccine used for the active prevention of Japanese encephalitis, a serious central nervous system infection caused by the Japanese encephalitis virus (JEV) and transmitted by mosquitoes. Developed by companies such as Liaoning Chengda Biotechnology, this specific formulation involves growing the virus in Vero cell cultures, followed by inactivation (usually with formaldehyde) and purification. The vaccine is often produced in a freeze-dried (lyophilized) form to enhance stability and shelf life. It works by inducing the production of neutralizing antibodies against JEV, providing protection to individuals living in or traveling to endemic regions. Clinical trials, including Phase IV safety studies, have been conducted to evaluate its performance as a booster dose in pediatric populations, comparing different manufacturers' formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on japanese encephalitis vaccine (vero cell), inactivated.